Market Research Logo

Lung Adenocarcinoma - Pipeline Review, H2 2015

Lung Adenocarcinoma - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Lung Adenocarcinoma - Pipeline Review, H2 2015’, provides an overview of the Lung Adenocarcinoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Lung Adenocarcinoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Lung Adenocarcinoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Lung Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Lung Adenocarcinoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Lung Adenocarcinoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Lung Adenocarcinoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Lung Adenocarcinoma Overview
Therapeutics Development
Pipeline Products for Lung Adenocarcinoma - Overview
Pipeline Products for Lung Adenocarcinoma - Comparative Analysis
Lung Adenocarcinoma - Therapeutics under Development by Companies
Lung Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes
Lung Adenocarcinoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Lung Adenocarcinoma - Products under Development by Companies
Lung Adenocarcinoma - Products under Investigation by Universities/Institutes
Lung Adenocarcinoma - Companies Involved in Therapeutics Development
Amgen Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Axelar AB
Bayer AG
Boehringer Ingelheim GmbH
Eisai Co., Ltd.
Genentech, Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Immunomedics, Inc.
Incyte Corporation
Johnson & Johnson
Morphotek, Inc.
Pfizer Inc.
Sanofi
VG Life Sciences, Inc.
Vichem Chemie Research Ltd.
Lung Adenocarcinoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
afatinib dimaleate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AV-203 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AXL-1717 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD-6738 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BAY-1163877 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dacomitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DBPR-112 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EB-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
farletuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
hydroxychloroquine + sorafenib tosylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-42756493 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lenvatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MAG-Tn3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
poziotinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Agonize Interferon Lamda Receptor 1 for Oncology and Infectious Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR-408701 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit EGFR for Non-Small Cell Lung Cancer and Lung Adenocarcinoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SNX-5422 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
solitomab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TdCyd - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine to Target CD40L and GM-CSF for Metastatic Lung Adenocarcinoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VAL-401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lung Adenocarcinoma - Recent Pipeline Updates
Lung Adenocarcinoma - Dormant Projects
Lung Adenocarcinoma - Product Development Milestones
Featured News & Press Releases
May 29, 2015: Spectrum Pharmaceuticals Highlights Abstract of Clinical Data For Poziotinib at the 2015 ASCO Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Lung Adenocarcinoma, H2 2015
Number of Products under Development for Lung Adenocarcinoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Lung Adenocarcinoma - Pipeline by Amgen Inc., H2 2015
Lung Adenocarcinoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
Lung Adenocarcinoma - Pipeline by AstraZeneca Plc, H2 2015
Lung Adenocarcinoma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
Lung Adenocarcinoma - Pipeline by Axelar AB, H2 2015
Lung Adenocarcinoma - Pipeline by Bayer AG, H2 2015
Lung Adenocarcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Lung Adenocarcinoma - Pipeline by Eisai Co., Ltd., H2 2015
Lung Adenocarcinoma - Pipeline by Genentech, Inc., H2 2015
Lung Adenocarcinoma - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015
Lung Adenocarcinoma - Pipeline by Immunomedics, Inc., H2 2015
Lung Adenocarcinoma - Pipeline by Incyte Corporation, H2 2015
Lung Adenocarcinoma - Pipeline by Johnson & Johnson, H2 2015
Lung Adenocarcinoma - Pipeline by Morphotek, Inc., H2 2015
Lung Adenocarcinoma - Pipeline by Pfizer Inc., H2 2015
Lung Adenocarcinoma - Pipeline by Sanofi, H2 2015
Lung Adenocarcinoma - Pipeline by VG Life Sciences, Inc., H2 2015
Lung Adenocarcinoma - Pipeline by Vichem Chemie Research Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Lung Adenocarcinoma Therapeutics - Recent Pipeline Updates, H2 2015
Lung Adenocarcinoma - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Lung Adenocarcinoma, H2 2015
Number of Products under Development for Lung Adenocarcinoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report